Enanta Pharmaceuticals Inc (ENTA) shareholders
Close on Nov 17, 2026Market cap $253.10MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Janus Henderson Group PLC Joint filing with Janus Henderson Biotech Innovation Master Fund Ltd (10.60%) | 3,494,068 | 12.10% | 13G (passive) | Oct 31, 2025 |
| Giauque, Nicolas Joint filing with Wehrly, Mark C. (9.80%), Dapice Joshua J. (9.80%) and 13 more | 2,816,862 | 9.80% | 13G (passive) amendment | Dec 31, 2025 |
| Dunn Hannah E. Joint filing with Farallon Capital Management, L.L.C. (8.30%), Dapice Joshua J. (8.30%) and 13 more | 2,418,202 | 8.30% | 13G (passive) amendment | Jun 30, 2026 |
| Linn, Michael G. Joint filing with Wehrly, Mark C. (9.90%), Dapice Joshua J. (9.90%) and 15 more | 2,108,262 | 9.90% | 13G (passive) amendment | Dec 31, 2024 |
| Jay R. Luly, Ph.D. | 1,703,616 | 7.70% | 13D (active) amendment | Feb 12, 2025 |
| BlackRock, Inc. | 1,673,483 | 7.80% | 13G (passive) amendment | Mar 31, 2025 |
| BlackRock Portfolio Management LLC | 1,560,091 | 5.40% | 13G (passive) | Sep 30, 2026 |
| Millennium Management LLC Joint filing with Millennium Group Management LLC (6.50%), Israel A. Englander (6.50%) and 1 more | 1,382,273 | 6.50% | 13G (passive) | Jan 14, 2025 |
| Krensavage Asset Management, LLC | 1,086,024 | 5.10% | 13G (passive) | Feb 22, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of ENTA | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Jupiter Topco LLC | 3,654,920 | 12.55% | $53.25M | New | 0.02% |
| BlackRock, Inc. | 3,244,448 | 11.14% | $47.30M | +140,680 | 0.00% |
| Krensavage Asset Management, LLC | 2,866,138 | 9.84% | $41.79M | – | 15.88% |
| Farallon Capital Management LLC | 2,418,202 | 8.30% | $35.26M | −453,660 | 0.16% |
| Deep Track Capital, LP | 1,444,167 | 4.96% | $21.06M | −512,700 | 0.31% |
| ADAR1 Capital Management, LLC | 1,344,510 | 4.62% | $19.60M | +1,293,153 | 0.90% |
| Vanguard Capital Management LLC | 1,211,769 | 4.16% | $17.67M | +33,720 | 0.00% |
| Spruce Street Capital LP | 1,088,731 | 3.74% | $15.87M | +156,133 | 3.11% |
| Acadian Asset Management LLC | 1,078,317 | 3.70% | $15.71M | +198,294 | 0.02% |
| Vanguard Portfolio Management LLC | 1,011,494 | 3.47% | $14.75M | +62,590 | 0.00% |
| Geode Capital Management, LLC | 776,634 | 2.67% | $11.33M | +51,573 | 0.00% |
| Millennium Management LLC | 643,967 | 2.21% | $9.39M | −238,130 | 0.00% |
| State Street Corp | 576,117 | 1.98% | $8.40M | +14,011 | 0.00% |
| Renaissance Technologies LLC | 557,600 | 1.91% | $8.13M | −107,658 | 0.01% |
| Hillsdale Investment Management Inc. | 468,000 | 1.61% | $6.82M | +32,490 | 0.16% |
| Goldman Sachs Group Inc | 464,649 | 1.60% | $6.77M | +199,561 | 0.00% |
| Morgan Stanley | 315,729 | 1.08% | $4.60M | +6,218 | 0.00% |
| Charles Schwab Investment Management Inc | 301,151 | 1.03% | $4.39M | +6,180 | 0.00% |
| Dimensional Fund Advisors LP | 282,682 | 0.97% | $4.12M | +79,430 | 0.00% |
| Northern Trust Corp | 259,696 | 0.89% | $3.79M | +18,728 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 122 | 27M | 93.6% | 13 / 47 | 38 / 19 | 7M | 2M |
| Q1 2026 | 133 | 27M | 91.9% | 24 / 49 | 33 / 21 | 4M | 2M |
| Q4 2025 | 132 | 26M | 90.6% | 36 / 45 | 28 / 24 | 10M | 3M |
| Q3 2025 | 122 | 19M | 65.6% | 25 / 33 | 42 / 11 | 3M | 3M |
| Q2 2025 | 108 | 18M | 63.3% | 15 / 34 | 43 / 17 | 1M | 1M |
| Q1 2025 | 110 | 19M | 64.0% | 20 / 36 | 38 / 17 | 2M | 3M |
| Q4 2024 | 108 | 20M | 68.4% | 23 / 35 | 31 / 27 | 3M | 5M |
| Q3 2024 | 112 | 21M | 73.7% | 18 / 38 | 31 / 6 | 4M | 3M |
| Q2 2024 | 101 | 22M | 76.5% | 11 / 33 | 44 / 18 | 1M | 6M |
| Q1 2024 | 108 | 27M | 91.5% | 16 / 26 | 51 / 14 | 8M | 3M |
| Q4 2023 | 106 | 21M | 73.3% | 15 / 41 | 41 / 42 | 5M | 3M |
| Q3 2023 | 133 | 20M | 69.2% | 25 / 45 | 45 / 25 | 5M | 5M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
170 funds held ENTA in Q2 2026, 51% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of ENTA | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 877,120 | 3.01% | $12.79M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 731,781 | 2.51% | $10.67M | 0.01% | Jun 30, 2026 |
| BlackRock Health Sciences Opportunities Portfolio | 492,001 | 1.69% | $6.47M | 0.11% | May 29, 2026 |
| Fidelity Small Cap Index Fund | 307,927 | 1.06% | $3.88M | 0.01% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 301,261 | 1.03% | $4.39M | 0.00% | Jun 30, 2026 |
| Vanguard Strategic Small-Cap Equity Fund | 280,927 | 0.96% | $4.10M | 0.13% | Jun 30, 2026 |
| iShares Biotechnology ETF | 194,701 | 0.67% | $2.84M | 0.03% | Jun 30, 2026 |
| Vanguard Strategic Equity Fund | 180,741 | 0.62% | $2.64M | 0.02% | Jun 30, 2026 |
| Vanguard Explorer Fund | 140,620 | 0.48% | $1.77M | 0.01% | Jul 31, 2026 |
| Fidelity Extended Market Index Fund | 139,841 | 0.48% | $1.84M | 0.00% | May 31, 2026 |
| Vanguard Russell 2000 Index Fund | 139,763 | 0.48% | $1.84M | 0.01% | May 31, 2026 |
| iShares Russell 2000 Value ETF | 137,426 | 0.47% | $2.00M | 0.01% | Jun 30, 2026 |
| Small Company Growth Portfolio | 136,247 | 0.47% | $1.99M | 0.12% | Jun 30, 2026 |
| Schwab U.S. Small-Cap ETF | 128,383 | 0.44% | $1.69M | 0.01% | May 31, 2026 |
| iShares Russell 2000 Growth ETF | 123,846 | 0.43% | $1.81M | 0.01% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Jay R. Luly | President and CEO, Director | 871,871 | 2.99% | Feb 13, 2026 |
| Scott T. Rottinghaus | Chief Medical Officer | 23,787 | 0.08% | Aug 10, 2026 |
| Yat Sun Or | Chief Scientific Officer | 374,854 | 1.29% | Feb 13, 2026 |
| Brendan Luu | Chief Business Officer | 44,891 | 0.15% | Feb 13, 2026 |
| Tara Lynn Kieffer | Chief Product Strategy Officer | 32,195 | 0.11% | Feb 13, 2026 |
| Matthew Paul Kowalsky | Chief Legal Officer | 3,591 | 0.01% | Feb 13, 2026 |
| Harry R. Trout III | See Remarks | 16,348 | 0.06% | Dec 5, 2025 |
| Kathleen S. Capps | See Remarks | 8,377 | 0.03% | Dec 5, 2025 |
| Paul J. Mellett | Chief Fin. & Admin Officer | 99,210 | 0.34% | Feb 14, 2025 |
| Lesley Russell | Director | – | – | Mar 13, 2026 |
| Yujiro S. Hata | Director | – | – | Mar 13, 2026 |
| Kristine Peterson | Director | – | – | Mar 13, 2026 |
| Mark G. Foletta | Director | – | – | Mar 13, 2026 |
| Bruce L. A. Carter | Director | 0 | – | Mar 13, 2026 |
| Terry Vance | Director | 5,800 | 0.02% | Mar 13, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Scott T. Rottinghaus Chief Medical Officer | Aug 8, 2026 | Tax withholding | −1,467 | $13.34 | $19.57K | 23,787 |
| Yat Sun Or Chief Scientific Officer | Feb 12, 2026 | Tax withholding | −3,413 | $14.25 | $48.64K | 374,854 |
| Yat Sun Or Chief Scientific Officer | Feb 12, 2026 | Award | +1,650 | – | – | 373,042 |
| Yat Sun Or Chief Scientific Officer | Feb 12, 2026 | Award | +5,225 | – | – | 378,267 |
| Jay R. Luly President and CEO, Director | Feb 12, 2026 | Tax withholding | −6,155 | $14.25 | $87.71K | 871,871 |
| Jay R. Luly President and CEO, Director | Feb 12, 2026 | Award | +15,200 | – | – | 878,026 |
| Jay R. Luly President and CEO, Director | Feb 12, 2026 | Award | +4,800 | – | – | 862,826 |
| Tara Lynn Kieffer Chief Product Strategy Officer | Feb 12, 2026 | Award | +1,575 | – | – | 32,195 |
| Tara Lynn Kieffer Chief Product Strategy Officer | Feb 12, 2026 | Award | +4,987 | – | – | 37,182 |
| Tara Lynn Kieffer Chief Product Strategy Officer | Feb 12, 2026 | Tax withholding | −3,257 | $14.25 | $46.41K | 33,925 |
| Matthew Paul Kowalsky Chief Legal Officer | Feb 12, 2026 | Tax withholding | −1,902 | $14.25 | $27.10K | 3,591 |
| Matthew Paul Kowalsky Chief Legal Officer | Feb 12, 2026 | Award | +1,318 | – | – | 1,318 |
| Matthew Paul Kowalsky Chief Legal Officer | Feb 12, 2026 | Award | +4,175 | – | – | 5,493 |
| Brendan Luu Chief Business Officer | Feb 12, 2026 | Award | +4,987 | – | – | 44,891 |
| Brendan Luu Chief Business Officer | Feb 12, 2026 | Award | +1,575 | – | – | 39,904 |
| Brendan Luu Chief Business Officer | Feb 12, 2026 | Tax withholding | −3,257 | $14.25 | $46.41K | 41,634 |
| Scott T. Rottinghaus Chief Medical Officer | Feb 12, 2026 | Award | +1,650 | – | – | 23,442 |
| Scott T. Rottinghaus Chief Medical Officer | Feb 12, 2026 | Tax withholding | −3,413 | $14.25 | $48.64K | 25,254 |
| Scott T. Rottinghaus Chief Medical Officer | Feb 12, 2026 | Award | +5,225 | – | – | 28,667 |
| Harry R. Trout III See Remarks | Dec 5, 2025 | Sale | −542 | $14.23 | $7.71K | 16,348 |
| Tara Lynn Kieffer Chief Product Strategy Officer | Dec 5, 2025 | Sale | −2,106 | $14.23 | $29.97K | 30,620 |
| Jay R. Luly President and CEO, Director | Dec 5, 2025 | Sale | −4,743 | $14.23 | $67.49K | 858,026 |
| Brendan Luu Chief Business Officer | Dec 5, 2025 | Sale | −1,394 | $14.23 | $19.84K | 38,329 |
| Scott T. Rottinghaus Chief Medical Officer | Dec 5, 2025 | Sale | −798 | $14.23 | $11.36K | 21,792 |
| Yat Sun Or Chief Scientific Officer | Dec 5, 2025 | Sale | −2,390 | $14.23 | $34.01K | 371,392 |
| Kathleen S. Capps See Remarks | Dec 5, 2025 | Sale | −323 | $14.23 | $4.60K | 8,377 |
| Kathleen S. Capps See Remarks | Dec 2, 2025 | Sale | −207 | $13.96 | $2.89K | 8,700 |
| Harry R. Trout III See Remarks | Dec 2, 2025 | Sale | −380 | $13.96 | $5.30K | 16,890 |
| Jay R. Luly President and CEO, Director | Dec 1, 2025 | Tax withholding | −1,885 | $14.12 | $26.62K | 862,769 |
| Kathleen S. Capps See Remarks | Dec 1, 2025 | Tax withholding | −85 | $14.12 | $1.20K | 8,907 |
| Brendan Luu Chief Business Officer | Dec 1, 2025 | Tax withholding | −498 | $14.12 | $7.03K | 39,723 |
| Yat Sun Or Chief Scientific Officer | Dec 1, 2025 | Tax withholding | −753 | $14.12 | $10.63K | 373,782 |
| Tara Lynn Kieffer Chief Product Strategy Officer | Dec 1, 2025 | Tax withholding | −753 | $14.12 | $10.63K | 32,726 |
| Harry R. Trout III See Remarks | Dec 1, 2025 | Tax withholding | −105 | $14.12 | $1.48K | 17,270 |
| Kathleen S. Capps See Remarks | Nov 25, 2025 | Award | +3,163 | – | – | 8,992 |
| Harry R. Trout III See Remarks | Nov 25, 2025 | Award | +6,463 | – | – | 17,375 |
| Scott T. Rottinghaus Chief Medical Officer | Aug 8, 2025 | Tax withholding | −2,217 | $6.99 | $15.50K | 22,590 |
| Jay R. Luly President and CEO, Director | Feb 12, 2025 | Tax withholding | −7,484 | $5.59 | $41.84K | 864,654 |
| Jay R. Luly President and CEO, Director | Feb 12, 2025 | Award | +25,500 | – | – | 872,138 |
| Tara Lynn Kieffer Chief Product Strategy Officer | Feb 12, 2025 | Tax withholding | −3,326 | $5.59 | $18.59K | 33,479 |
| Tara Lynn Kieffer Chief Product Strategy Officer | Feb 12, 2025 | Award | +7,500 | – | – | 36,805 |
| Scott T. Rottinghaus Chief Medical Officer | Feb 12, 2025 | Tax withholding | −2,861 | $5.59 | $15.99K | 24,807 |
| Scott T. Rottinghaus Chief Medical Officer | Feb 12, 2025 | Award | +9,750 | – | – | 27,668 |
| Brendan Luu Chief Business Officer | Feb 12, 2025 | Tax withholding | −3,326 | $5.59 | $18.59K | 40,221 |
| Brendan Luu Chief Business Officer | Feb 12, 2025 | Award | +7,500 | – | – | 43,547 |
| Paul J. Mellett Chief Fin. & Admin Officer | Feb 12, 2025 | Award | +7,500 | – | – | 99,210 |
| Paul J. Mellett Chief Fin. & Admin Officer | Feb 12, 2025 | Tax withholding | −3,326 | $5.59 | $18.59K | 95,884 |
| Yat Sun Or Chief Scientific Officer | Feb 12, 2025 | Award | +9,750 | – | – | 378,859 |
| Yat Sun Or Chief Scientific Officer | Feb 12, 2025 | Tax withholding | −4,324 | $5.59 | $24.17K | 374,535 |
| Jay R. Luly President and CEO, Director | Feb 12, 2025 | Buy | +45,000 | $5.69 | $256.05K | 846,638 |
| Tara Lynn Kieffer Chief Product Strategy Officer | Dec 6, 2024 | Sale(10b5-1 plan) | −2,283 | $8.06 | $18.40K | 29,305 |
| Jay R. Luly President and CEO, Director | Dec 6, 2024 | Sale(10b5-1 plan) | −5,142 | $8.06 | $41.44K | 801,638 |
| Paul J. Mellett Chief Fin. & Admin Officer | Dec 6, 2024 | Sale(10b5-1 plan) | −2,591 | $8.06 | $20.88K | 91,710 |
| Yat Sun Or Chief Scientific Officer | Dec 6, 2024 | Sale(10b5-1 plan) | −2,591 | $8.06 | $20.88K | 369,109 |
| Scott T. Rottinghaus Chief Medical Officer | Dec 6, 2024 | Sale(10b5-1 plan) | −866 | $8.06 | $6.98K | 17,918 |
| Brendan Luu Chief Business Officer | Dec 6, 2024 | Sale(10b5-1 plan) | −2,283 | $8.06 | $18.40K | 36,047 |
| Brendan Luu Chief Business Officer | Dec 1, 2024 | Tax withholding | −753 | $8.60 | $6.48K | 38,330 |
| Yat Sun Or Chief Scientific Officer | Dec 1, 2024 | Tax withholding | −1,595 | $8.60 | $13.72K | 371,700 |
| Jay R. Luly President and CEO, Director | Dec 1, 2024 | Tax withholding | −3,829 | $8.60 | $32.93K | 806,780 |
| Paul J. Mellett Chief Fin. & Admin Officer | Dec 1, 2024 | Tax withholding | −1,595 | $8.60 | $13.72K | 94,301 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Enanta Pharmaceuticals's stock actually held short. Settlement fails (shares not delivered on time) peaked at 5,934 shares on Sep 23, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Jay R. Luly Officer, Director | Dec 5, 2025 | 4,743 | $67.54K | Dec 5, 2025 | Restricted Stock Unit Vesting |
| Scott T. Rottinghaus Officer | Jul 11, 2024 | 11,945 | $178.70K | Jul 11, 2024 | RSU Release |
| Tara Lynn Kieffer Officer | Jun 17, 2024 | 7,266 | $92.35K | Jun 17, 2024 | PSU Release |
| Terry Vance Director | Dec 12, 2023 | 15,295 | $138.57K | Dec 13, 2023 | Initial Public Offering |
Congress trades
3 trades in Enanta Pharmaceuticals reported by 2 members of the House
| Member | Type | Traded | Amount | Filed |
|---|---|---|---|---|
| Daniel Goldman NY10 | Sold | Jul 12, 2023 | $1K–15K | Aug 13, 2023 |
| Thomas MacArthur NJ03 · joint account | Sold | May 27, 2015 | $1K–15K | Jun 7, 2015 |
| Thomas MacArthur NJ03 · joint account | Bought | Mar 20, 2015 | $1K–15K | Apr 11, 2015 |
See a number that looks wrong?